Fritextsökning
Artiklar per år
Innehållstyper
-
Now it’s settled: The International Vaccine Institute will be located in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified the agreement, which means that a branch of the institute will be located in Stockholm.
-
Start-up developing ”digital twin” received award during the EIT Health Summit
A biotech company, a medtech company and a company in digital health were on the podium when the EIT Health Catapult awarded its winners.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
Pharm Assist köps av ny koncern inom life science-tjänster
Konsultbolaget Pharm Assist Sweden har köpts upp och kommer tillsammans med det norska investmentbolaget Serendipity och kontraktsforskningsföretaget Link Medical att ingå i en ny nordeuropeisk koncern för tjänster inom life science.
-
Serendipity går in som storägare i Link
Det norska kontraktsforskningsföretaget Link Medical ingår ett partnerskap med Serendipity partners, som går in som delägare och långsiktig investerare i bolaget.
-
Paolo Macchiarini in court – “The sole intent was to cure”
Paolo Macchiarini’s surgical procedure was illegal, life-threatening and caused severe and prolonged suffering to patients the prosecution claimed when the trial against the Italian surgeon began on Wednesday last week.
-
We will now publish more news in English – and offer yet another newsletter
Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.
-
Elicera develops CAR-T against solid tumours – may become the first in the world
Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.
-
Life Science Sweden´s international issue is on its way
A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.
-
Patient som fick grishjärta återhämtar sig – inga tecken på avstötning
Den amerikanske man som fick ett genmodifierat grishjärta transplanterat i början av året återhämtar sig fortfarande på sjukhus. Efter fem veckor syns inga tecken på avstötning, enligt läkare.
-
The route to vaccines for everyone: “We did not just sit around and wait”
The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.
-
Lockdown-studie kritiseras även i USA
I USA har den uppmärksammade metastudie som uppger att knappt några liv har räddats med hjälp av lockdowns blivit kraftigt ifrågasatt av forskare.
-
Giulia Gaudenzi: Innovation for good
"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences", writes Giulia Gaudenzi in a column.